Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 25, 2024 10:57 ET | Source: Research and Markets

U.S. Inflammatory Bowel Disease Treatment Market Trends Analysis Report 2024-2030 Featuring Biogen, Novartis, Eli Lilly & Co, UCB, Celltrion, Merck & Co, and Johnson & Johnson

Dublin, June 25, 2024 (GLOBE NEWSWIRE) -- The "U.S. Inflammatory Bowel Disease Treatment Market Size, Share & Trends Analysis Report by Type, Drug Class, Route Of Administration, Distribution...
March 22, 2024 10:14 ET | Source: Spherix Global Insights

Gastroenterologists Slow to Adopt Eli Lilly’s Omvoh, Pfizer’s Velsipity, and Takeda’s subcutaneous formulation of Entyvio for the Treatment of Ulcerative Colitis, but Future Projections Reveal a Highly Evolving Market

Exton, Pennsylvania, March 22, 2024 (GLOBE NEWSWIRE) -- The end of 2023 introduced several new treatment options for patients suffering from ulcerative colitis (UC). Among them is Eli Lilly’s Omvoh...
November 30, 2023 10:59 ET | Source: Spherix Global Insights

When it Comes to Treating Ulcerative Colitis, US Gastroenterologists May be Betting it All on JAK…

Exton, Pennsylvania, Nov. 30, 2023 (GLOBE NEWSWIRE) -- With the Ulcerative Colitis (UC) market set to heat up in the coming months, the JAK class seems poised to become a dominant treatment,...
November 13, 2023 09:22 ET | Source: Spherix Global Insights

US Gastroenterologist Projections Suggest Significant Shift in Ulcerative Colitis Landscape Afoot, with Launches of Eli Lilly's Omvoh, Pfizer's Velsipity, Takeda's Subcutaneous Entyvio, and Celltrion's Zymfentra

Exton, Pennsylvania, Nov. 13, 2023 (GLOBE NEWSWIRE) -- In the past two months, the landscape of available treatments for ulcerative colitis (UC) has undergone a significant expansion, marked by the...